Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Shares of Kaleido Biosciences are plunging after the company announced its intentions to cease all company operations, lay off its remaining staff and delist from the Nasdaq Exchange.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
The U.S. FDA greenlit China-based Triastek’s IND Application for its 3D printed drug product, T20, for cardiovascular and clotting disorders.
Alnylam Pharmaceuticals issued a proxy filing ahead of its May 18, 2022, Annual Meeting of Stockholders to inform stockholders of several items they can vote on at the end of the meeting.
The partnership framework agreement allows Moderna and U of T to collaborate across a broad variety of areas, ranging from molecular genetics to biomedical engineering, biochemistry and more.
GENFIT delivered on its promise to improve its financial situation in the year to December 31, 2021, posting an income of $40.8 million USD from a loss of $20.3 million in the year prior.
Researchers at the Babraham Research Institute have developed a new technique for rejuvenating skin cells, which can rewind the biological clock of patients by about 30 years.
The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.
Janssen Pharmaceutical, under parent organization Johnson & Johnson, secured an arbitrary win this week that results in royalty decisions stemming from licensing and marketing of daratumumab.
Classical psychedelics are showing promising results in treating opioid use disorder. How they aim to do that can be found here in the article.
COVID-19 has killed more than six million people worldwide and almost one million in the U.S. And the pandemic isn’t over yet. Read on for that and more updates about COVID-19.
GeoVax is conducting two Phase II COVID-19 vaccine clinical trials with its GEO-CMO4S1 vaccine. One of the trials is among immunocompromised patients.